Top 10 Suvorexant (Belsomra) Generic Manufacturers in Israel
The pharmaceutical market in Israel has witnessed significant growth in recent years, particularly in the area of generics. The country is known for its advanced research and development capabilities, alongside a robust regulatory framework that supports the production of high-quality generic medications. As of 2023, the Israeli pharmaceutical market is valued at approximately $5 billion, with generics accounting for about 30% of this figure. Notably, the demand for sleep aids, including Suvorexant (Belsomra), has surged, prompting local manufacturers to enhance their production capacities and diversify their portfolios.
1. Teva Pharmaceutical Industries Ltd.
Teva is the largest generic drug manufacturer in Israel and a global leader in the pharmaceutical industry. With a market share of around 10% in the global generic market, Teva produces various medications, including generic Suvorexant. In 2022, Teva reported revenues of approximately $16 billion, highlighting its significant role in the generic segment.
2. Taro Pharmaceutical Industries Ltd.
Taro is known for its diverse portfolio of generic medications and has a strong presence in the North American market. The company specializes in dermatological and psychiatric products, with a growing focus on sleep disorders. Taro’s revenue reached $500 million in 2022, with generics contributing substantially to its earnings.
3. Perrigo Company plc
Perrigo, originally from the U.S., operates a significant manufacturing facility in Israel. The company specializes in over-the-counter and prescription generic medications. In 2023, Perrigo’s revenue from its Israeli operations was approximately $1 billion, showcasing its impact on the generic sleep aid market, including Suvorexant.
4. Abic Manufacturing Ltd.
Abic, a subsidiary of Teva, is dedicated to producing high-quality generics, including various medications for sleep disorders. The company has embraced modern manufacturing practices, contributing to its efficiency and production volume. In 2022, Abic had a production capacity of over 5 million units per year for its generic products.
5. Israel Pharmaceutical Industries (IPI)
IPI is a prominent player in the Israeli pharmaceutical landscape, producing a range of generic medications. Their focus on research and development has allowed them to enter the sleep aid market with generic versions of Suvorexant. IPI’s annual revenue reached $300 million in 2022, with substantial growth expected in the coming years.
6. Oramed Pharmaceuticals Inc.
Oramed focuses on developing innovative solutions for diabetes and sleep disorders. The company has ventured into generic formulations, including Suvorexant, to address the growing need for effective sleep aids. In 2023, Oramed’s revenue was about $50 million, indicating a steady growth trajectory.
7. Kamada Ltd.
Kamada is known for its specialized biopharmaceuticals but has expanded into generic drug production. The company’s strategic initiatives have led to the development of a generic version of Suvorexant, which is expected to capture a portion of the market. In 2022, Kamada’s revenue was approximately $100 million.
8. Dexcel Pharma Technologies Ltd.
Dexcel Pharma has established itself in the field of generics and specialty pharmaceuticals. The company is focused on producing high-quality medications for various therapeutic areas, including sleep disorders. Dexcel’s annual revenue stands at around $200 million, with generics contributing significantly to this figure.
9. Generic Drug Manufacturers (GDM) Ltd.
GDM specializes in producing a wide range of generic pharmaceuticals, including those for mental health and sleep disorders. The company has invested in modern facilities to enhance its production capabilities. In 2022, GDM reported revenues of approximately $150 million, with a growing focus on the sleep aid market.
10. Efrat Pharmaceuticals Ltd.
Efrat Pharmaceuticals is a smaller manufacturer that focuses on niche markets within the pharmaceutical sector. The company has recently initiated the production of generic Suvorexant to meet the rising demand for sleep medications. Efrat’s revenue was around $30 million in 2022, indicating its potential for growth in the industry.
Insights
The generic Suvorexant market in Israel is poised for substantial growth, driven by an increasing prevalence of sleep disorders and a growing awareness of mental health issues. As of 2023, the market for sleep aids in Israel is projected to reach over $200 million, with generics expected to capture a larger share due to their cost-effectiveness. The trend toward consolidation among pharmaceutical companies may lead to increased competition, further driving innovation in the production of sleep aids. Additionally, advancements in manufacturing technologies and regulatory support will likely enhance production capacities and quality, ensuring that Israeli manufacturers remain competitive in the global landscape.
Related Analysis: View Previous Industry Report
